• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

InsureTech Chatbot Platform Sensely Raises $15M to Modernize Member Experience

Share:

November 4, 2019

– Digital health and InsureTech chatbot platform Sensely announced it has raised $15M in funding led by Aflac Corporate Ventures, the venture arm of Aflac Inc.

– The funding brings expanded commercial pathways to Sensely, with markets serving over 60 million members and representing over $200MM in annual recurring revenue opportunities.  

At HLTH 2019, Sensely, a San Francisco, CA-based digital health and InsureTech platform that modernizes member experience while lowering costs, announced that it has raised $15M in funding led by Aflac Corporate Ventures, the venture arm of Aflac Inc., the largest supplemental insurance provider in the United States. The funding includes participation from strategic investors that represent the range of current Sensely target markets in insurance, hospital systems, and pharmaceuticals.

Engage Your Members. Reduce Your Costs

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Founded in 2013, Sensely’s avatar and chatbot-based platforms assist insurance plan members and patients with the insurance services and healthcare resources they need, when they need it. By utilizing Sensely’s scalable platform technology architecture, enterprises can converse with their members in an entirely new way, combining the empathy of human conversation with the efficiency and scalability of the technology. With offices in London and San Francisco, Sensely’s global teams provide virtual assistant solutions to insurance companies, pharmaceutical clients, and hospital systems worldwide.

Recent Traction

The capital injection comes at a time when Sensely is seeing increasing demand for its multi-lingual AI platform, which uses a voice-enabled character interface, and incorporates into existing enterprise technology infrastructure. Sensely is currently deployed with enterprise customers in the United States, United Kingdom, United Arab Emirates, Netherlands, China, Hong Kong, Japan, Switzerland, and Australia. Customers are using the platform for a diversified set of high-value use cases, including symptom checking, insurance underwriting, claims management, medication management, and remote patient monitoring.

Expanding Commercialization Efforts

Sensely plans to use the latest round of funding to expand its burgeoning commercialization efforts and extend its platform leadership. With the large contingent of strategic investors, the financing also brings expanded commercial pathways to Sensely, with markets serving over 60 million members and representing over $200MM in annual recurring revenue opportunities.

“We’re delighted by the opportunity to work with our new investment partners,” said Adam Odessky, CEO and Co-founder of Sensely. “While we are pleased with our progress over the past year, especially the rollout of our software development kit, we have many important challenges ahead. This funding will ensure that we can strike a balanced approach, continuing to serve our existing partners, while also evolving the platform for the next wave of requested capabilities.”

Source: HIT Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Bayer approached Elanco about possible deal – BloombergBayer approached Elanco about possible deal – Bloomberg
  • Black Diamond Therapeutics Closes $85 Million Series C FinancingBlack Diamond Therapeutics Closes $85 Million Series C Financing
  • 180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
  • Australian Medtech Startup Emerges from Stealth, Unveils Tomographic Ultrasound RobotAustralian Medtech Startup Emerges from Stealth, Unveils Tomographic Ultrasound Robot
  • Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0
  • Charles River Laboratories Acquires SAMDI TechCharles River Laboratories Acquires SAMDI Tech
  • One Drop Acquires Sano’s Continuous Glucose Sensing PlatformOne Drop Acquires Sano’s Continuous Glucose Sensing Platform
  • Alcon Announces Acquisition of Tear Film Innovations, Inc.Alcon Announces Acquisition of Tear Film Innovations, Inc.

Trending This Week

  • Immuno-Oncology Pipeline Cuts Explained
  • Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
  • USFDA Accepts Glenmark’s Application to Initiate a Human Trial of Molecules for Advanced Solid Tumors and Lymphomas
  • Concentra’s Buy Offer May Jeopardize Jounce’s Merger with Redx
  • Pfizer Acquires Seagen For $43B To Tackle Cancer
  • Janssen’s Novel Dengue Antiviral Demonstrates ‘strong Protection’ in Pre-Clinical Data

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications